专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004042032A2 CYTOGENETIC ABNORMALITIES THAT ARE PREDICTIVE OF RESPONSE TO THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA 审中-公开
标题翻译：对慢性淋巴细胞白血病治疗有反应的细胞因子异常
公开(公告)号：WO2004042032A2
公开(公告)日：2004-05-21
申请号：PCT/US2003/035225
申请日：2003-11-03
申请人： THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION , BYRD, John, C. , HEEREMA, Nyla, A.
发明人： BYRD, John, C. , HEEREMA, Nyla, A.
IPC分类号： C12N
CPC分类号： C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： Methods and kits are provided for predicting the response of patients with B-cell chronic lymphocytic leukemia (CLL) to treatment with agents that bind to the CD20 and CD 52 antigens on the surface of B lymphocytes. The methods of the present invention are for identifying patients who are refractory and patients who are responsive to therapy with such agents by analyzing the genome of cells obtained from the patients for the presence of specific chromosomal abnormalities, including del(17p13.1), and one or more of del(13q14.3), del(11q22.3) and trisomy 12. The methods are performed using appropriate cytogenetic analysis techniques, such as fluorescence in situ hybridization (FISH), with probes capable of detecting the specific cytogenetic abnormalities. Patients without del(17p13.1) but with del(13q14.3), del(11q22.3) or trisomy for chromosome 12, have been shown to be responsive to agents that bind CD20, such as rituximab. Patients with del(17p13.1) have been shown not to be responsive to rituximab, but are responsive to agents that bind CD52, such as alemtuzumab. By customizing treatment of CLL based on a patient’s cytogenetic profile, a improved outcome may be achieved for the patient, along with time and cost savings that are afforded by foregoing unnecessary therapy.
摘要翻译：提供方法和试剂盒，用于预测B细胞慢性淋巴细胞性白血病（CLL）患者对结合B淋巴细胞表面CD20和CD52抗原的药物的治疗反应。本发明的方法是通过分析从患者获得的细胞的基因组中鉴定特异性染色体异常的存在，包括del（17p13.1）和 del（13q14.3），del（11q22.3）和三体性12中的一种或多种。该方法使用适当的细胞遗传学分析技术进行，例如荧光原位杂交（FISH），具有能够检测特异性细胞遗传学异常的探针。没有del（17p13.1）但del（13q14.3），del（11q22.3）或染色体12的三体性的患者已被证明对结合CD20的药物如利妥昔单抗有反应。已证实del（17p13.1）患者对利妥昔单抗不敏感，但对结合CD52的药物（如阿仑单抗）有反应。通过根据患者的细胞遗传学特征定制CLL的治疗，可以为患者实现改善的结果，同时通过前述不必要的治疗提供的时间和成本节省。

2. 发明申请

WO2004042032A3 CYTOGENETIC ABNORMALITIES THAT ARE PREDICTIVE OF RESPONSE TO THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA 审中-公开
标题翻译：对慢性淋巴细胞白血病治疗有反应的细胞因子异常
公开(公告)号：WO2004042032A3
公开(公告)日：2005-07-07
申请号：PCT/US0335225
申请日：2003-11-03
申请人： UNIV OHIO STATE RES FOUND , BYRD JOHN C , HEEREMA NYLA A
发明人： BYRD JOHN C , HEEREMA NYLA A
IPC分类号： C12Q1/68 , G01N33/574 , C07H21/00
CPC分类号： C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： Methods and kits are provided for predicting the response of patients with B-cell chronic lymphocytic leukemia (CLL) to treatment with agents that bind to the CD20 and CD 52 antigens on the surface of B lymphocytes. The methods of the present invention are for identifying patients who are refractory and patients who are responsive to therapy with such agents by analyzing the genome of cells obtained from the patients for the presence of specific chromosomal abnormalities, including del(17p13.1), and one or more of del(13q14.3), del(11q22.3) and trisomy 12. The methods are performed using appropriate cytogenetic analysis techniques, such as fluorescence in situ hybridization (FISH), with probes capable of detecting the specific cytogenetic abnormalities. Patients without del(17p13.1) but with del(13q14.3), del(11q22.3) or trisomy for chromosome 12, have been shown to be responsive to agents that bind CD20, such as rituximab. Patients with del(17p13.1) have been shown not to be responsive to rituximab, but are responsive to agents that bind CD52, such as alemtuzumab. By customizing treatment of CLL based on a patient's cytogenetic profile, a improved outcome may be achieved for the patient, along with time and cost savings that are afforded by foregoing unnecessary therapy.
摘要翻译：提供方法和试剂盒，用于预测B细胞慢性淋巴细胞性白血病（CLL）患者对结合B淋巴细胞表面CD20和CD52抗原的药物的治疗反应。本发明的方法是通过分析从患者获得的细胞的基因组中鉴定特异性染色体异常的存在，包括del（17p13.1）和 del（13q14.3），del（11q22.3）和三体性12中的一种或多种。该方法使用适当的细胞遗传学分析技术进行，例如荧光原位杂交（FISH），具有能够检测特异性细胞遗传学异常的探针。没有del（17p13.1）但del（13q14.3），del（11q22.3）或染色体12的三体性的患者已被证明对结合CD20的药物如利妥昔单抗有反应。已证实del（17p13.1）患者对利妥昔单抗不敏感，但对结合CD52的药物（如阿仑单抗）有反应。通过根据患者的细胞遗传学特征定制CLL的治疗，可以为患者实现改善的结果，同时通过前述不必要的治疗提供的时间和成本节省。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式